NASDAQ:LIFE - aTyr Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.44 -0.02 (-4.32 %) (As of 05/21/2019 01:28 AM ET)Previous Close$0.4644Today's Range$0.44 - $0.474952-Week Range$0.38 - $1.37Volume146,961 shsAverage Volume386,580 shsMarket Capitalization$20.26 millionP/E RatioN/ADividend YieldN/ABeta2.51 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. The company has a collaboration with the University of Nebraska Medical Center for the development of neuropilin-2 receptor biology; and a research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases. The company was founded in 2005 and is headquartered in San Diego, California. Receive LIFE News and Ratings via Email Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:LIFE Previous Symbol CUSIP53217V10 CIK1339970 Webwww.atyrpharma.com Phone858-731-8389Debt Debt-to-Equity Ratio0.31 Current Ratio4.00 Quick Ratio4.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book0.69Profitability EPS (Most Recent Fiscal Year)($1.15) Net Income$-34,510,000.00 Net MarginsN/A Return on Equity-81.33% Return on Assets-51.98%Miscellaneous Employees42 Outstanding Shares45,742,000Market Cap$20.26 million Next Earnings Date8/13/2019 (Estimated) OptionableOptionable aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions What is aTyr Pharma's stock symbol? aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE." How were aTyr Pharma's earnings last quarter? aTyr Pharma Inc (NASDAQ:LIFE) announced its quarterly earnings results on Monday, May, 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. View aTyr Pharma's Earnings History. When is aTyr Pharma's next earnings date? aTyr Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for aTyr Pharma. What price target have analysts set for LIFE? 4 Wall Street analysts have issued 12-month target prices for aTyr Pharma's shares. Their forecasts range from $0.75 to $1.80. On average, they anticipate aTyr Pharma's stock price to reach $1.1833 in the next year. This suggests a possible upside of 167.1% from the stock's current price. View Analyst Price Targets for aTyr Pharma. What is the consensus analysts' recommendation for aTyr Pharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma. Has aTyr Pharma been receiving favorable news coverage? Media headlines about LIFE stock have trended somewhat negative on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. aTyr Pharma earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. Are investors shorting aTyr Pharma? aTyr Pharma saw a decrease in short interest in April. As of April 15th, there was short interest totalling 434,783 shares, a decrease of 33.8% from the March 29th total of 656,761 shares. Based on an average daily trading volume, of 338,705 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.9% of the company's shares are sold short. View aTyr Pharma's Current Options Chain. Who are some of aTyr Pharma's key competitors? Some companies that are related to aTyr Pharma include Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Applied Genetic Technologies (AGTC), Curis (CRIS), Cidara Therapeutics (CDTX), BioCardia (BCDA), Pharmacyte Biotech (PMCB), Entera Bio (ENTX), BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), Vical (VICL), Outlook Therapeutics (OTLK) and TRACON Pharmaceuticals (TCON). What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Crispr Therapeutics (CRSP), QUALCOMM (QCOM), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), Rigel Pharmaceuticals (RIGL) and Viking Therapeutics (VKTX). Who are aTyr Pharma's key executives? aTyr Pharma's management team includes the folowing people: Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 47)Ms. Jill M. Broadfoot, CFO & Principal Accounting Officer (Age 57)Dr. John D. Mendlein, Strategic Advisor & Director (Age 59)Dr. David J. King, Scientific Consultant (Age 60)Xiang-Lei Yang Ph.D., Founder When did aTyr Pharma IPO? (LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. Who are aTyr Pharma's major shareholders? aTyr Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Viking Global Investors LP (8.79%) and Renaissance Technologies LLC (4.22%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Ecor1 Capital Fund Qualified,, Jill Marie Broadfoot, John Mendlein, Nancy Krueger and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma. Which institutional investors are buying aTyr Pharma stock? LIFE stock was bought by a variety of institutional investors in the last quarter, including Viking Global Investors LP and Renaissance Technologies LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Jill Marie Broadfoot, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma. How do I buy shares of aTyr Pharma? Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is aTyr Pharma's stock price today? One share of LIFE stock can currently be purchased for approximately $0.4430. How big of a company is aTyr Pharma? aTyr Pharma has a market capitalization of $20.26 million. The biotechnology company earns $-34,510,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. aTyr Pharma employs 42 workers across the globe. What is aTyr Pharma's official website? The official website for aTyr Pharma is http://www.atyrpharma.com. How can I contact aTyr Pharma? aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected] MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 339 (Vote Outperform)Underperform Votes: 407 (Vote Underperform)Total Votes: 746MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Find a Trading Strategy That Works Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.